- Home
- RBOT vs VRCA Comparison
RBOT vs VRCA Comparison
Compare RBOT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | VRCA |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 32.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RBOT | VRCA |
|---|---|---|
| Price | $2.69 | $8.00 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 151.6K | ★ 402.7K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $30,829,000.00 |
| Revenue This Year | N/A | $373.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $2.44 | $3.28 |
| 52 Week High | $18.97 | $9.82 |
Technical Indicators
Market Signals| Indicator | RBOT | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 62.44 |
| Support Level | $2.70 | $7.82 |
| Resistance Level | $3.07 | $9.78 |
| Average True Range (ATR) | 0.34 | 1.18 |
| MACD | 0.09 | 0.10 |
| Stochastic Oscillator | 6.94 | 64.93 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.